TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37595029

Group type: EXPERIMENTAL
Intervention: mHealth app + booklet with patient-facing guidelines
Number of subjects: 74

Group type: COMPARATOR
Intervention: Booklet with guidelines alone
Number of subjects: 74
Study: 37595058

Group type: EXPERIMENTAL
Intervention: GATA2 enhancer mutation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CRISPR/Cas9-modified HL-60 cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Luciferase assays with the enhancer mutation
Number of subjects: 0
Study: 37595103

Group type: EXPERIMENTAL
Intervention: Baloxavir marboxil (single-dose)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Oseltamivir (twice-daily for 5 days)
Number of subjects: 94
Study: 37595843

Group type: EXPERIMENTAL
Intervention: Pregnancy
Number of subjects: 407

Group type: COMPARATOR
Intervention: No Pregnancy (Control)
Number of subjects: 407
Study: 37595984

Group type: EXPERIMENTAL
Intervention: Usual care plus two additional PoCUS performed at 2-hour intervals from the initial PoCUS (serial ultrasound group)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Usual care including a single cardiopulmonary PoCUS within 1 hour of arrival (control group)
Number of subjects: 206
Study: 37596006

Group type: EXPERIMENTAL
Intervention: NIHSS training and mobile application for scoring
Number of subjects: 447

Group type: COMPARATOR
Intervention: Standard stroke protocol (control group)
Number of subjects: 447
Study: 37596158

Group type: EXPERIMENTAL
Intervention: Tai-chi exercise for 12 months
Number of subjects: 15
Study: 37596191

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 172
Study: 37596281

Group type: EXPERIMENTAL
Intervention: Intranasal adenoviral vectored SARS-CoV-2 vaccine (BBV154)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Licensed intramuscular vaccine, Covaxin
Number of subjects: 0
Study: 37596280

Group type: EXPERIMENTAL
Intervention: CoVac-1 (one subcutaneous dose)
Number of subjects: 54
Study: 37596323

Group type: EXPERIMENTAL
Intervention: 4-channel NMES
Number of subjects: 17

Group type: COMPARATOR
Intervention: 2-channel NMES
Number of subjects: 17
Study: 37596391

Group type: EXPERIMENTAL
Intervention: RET-He
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ferritin
Number of subjects: 0
Study: 37596428

Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC) with Probenecid
Number of subjects: 0

Group type: COMPARATOR
Intervention: N-Acetylcysteine (NAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Probenecid
Number of subjects: 0
Study: 37596449

Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Systemic therapy alone
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) with complete cytoreduction (CC-0)
Number of subjects: 61
Study: 37596461

Group type: EXPERIMENTAL
Intervention: Experimental treatment (not specified dosage or duration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment (not specified dosage or duration)
Number of subjects: 0
Study: 37596524

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic resonance-guided focused ultrasound (MRgFUS) pallidothalamic tractotomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Demographic and clinical data collection
Number of subjects: 0
Study: 37596541

Group type: EXPERIMENTAL
Intervention: Cognitive intervention (neuropsychological psychoeducation)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Affective intervention (emotion management with cognitive-behavioural counselling)
Number of subjects: 130
Study: 37596549

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Elder Care (MBEC) program for 8 weeks
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study: 37596551

Group type: EXPERIMENTAL
Intervention: Functional tests including Lower Quarter Y-Balance Test (YBT-LQ), single-legged hop tests, isokinetic strength tests, and self-reported function measured with Banff Patellofemoral Instability Instrument 2.0 (BPII) and Norwich Patellar Instability score (NPI).
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Functional assessment at 6 months post-surgery.
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Extent of surgery (MPFL-R only vs combined surgery).
Number of subjects: 78
Study: 37596568

Group type: EXPERIMENTAL
Intervention: Therapeutic alliance during the first seven days of residential stay
Number of subjects: 44
Study: 37596613

Group type: EXPERIMENTAL
Intervention: Robot-assisted partial nephrectomy at low insufflation pressure (7 mmHg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Robot-assisted partial nephrectomy at standard insufflation pressure (12 mmHg)
Number of subjects: 0
Study: 37596658

Group type: EXPERIMENTAL
Intervention: clip + iodine seed
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: magnetic seed
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: carbon suspension
Number of subjects: 189

Group type: COMPARATOR
Intervention: clip + iodine seed, magnetic seed, carbon suspension
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: targeted lymph nodes (TLN)
Number of subjects: 189
Study: 37596887

Group type: EXPERIMENTAL
Intervention: Fugl-Meyer assessment (FM-LE)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Motricity Index total score (MI-LE)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Motricity Index ankle item (MI-ankle)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Center-of-pressure area (COP) during quiet 2-legged stance
Number of subjects: 48
Study: 37597095

Group type: EXPERIMENTAL
Intervention: Primary Hyperparathyroidism (PHPT)
Number of subjects: 41
Study: 37597153

Group type: EXPERIMENTAL
Intervention: Idecabtagene vicleucel (ide-cel) treatment
Number of subjects: 128
Study: 37597159

Group type: EXPERIMENTAL
Intervention: Guselkumab (subcutaneous 100 mg at weeks 0, 4, and every 8 weeks)
Number of subjects: 114
Study: 37597161

Group type: EXPERIMENTAL
Intervention: Rhythmic Auditory Stimulations (RAS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rhythmic Vibrotactile Stimulations (RVS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control Condition (CC)
Number of subjects: 10
Study: 37597246

Group type: EXPERIMENTAL
Intervention: Binimetinib (45 mg twice daily) plus Panitumumab (6 mg/kg every 2 weeks)
Number of subjects: 53
Study: 37597326

Group type: EXPERIMENTAL
Intervention: Adjunctive brivaracetam (BRV) treatment
Number of subjects: 257
Study: 37597507

Group type: EXPERIMENTAL
Intervention: Aerobic exercise on a bicycle ergometer
Number of subjects: 91

Group type: COMPARATOR
Intervention: Flexibility, strengthening, and balance training
Number of subjects: 91
Study: 37597522

Group type: EXPERIMENTAL
Intervention: Home-based albuminuria screening by urine collection device (UCD)
Number of subjects: 15074

Group type: EXPERIMENTAL
Intervention: Home-based albuminuria screening by smartphone application method
Number of subjects: 15074
Study: 37597523

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 1.5 mg plus piroxicam 40 mg
Number of subjects: 860

Group type: COMPARATOR
Intervention: Levonorgestrel 1.5 mg plus placebo
Number of subjects: 860
Study: 37597724

Group type: EXPERIMENTAL
Intervention: N8-GP (turoctocog alfa pegol; Esperoct)
Number of subjects: 81
Study: 37597750

Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Number of subjects: 304

Group type: COMPARATOR
Intervention: Pembrolizumab
Number of subjects: 304
Study: 37597856

Group type: EXPERIMENTAL
Intervention: Serratus anterior plane block
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 75
Study: 37597868

Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg
Number of subjects: 261
Study: 37597865

Group type: EXPERIMENTAL
Intervention: Prolonged fasting (PF) followed by time-restricted eating (TRE) for 12 months
Number of subjects: 180

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 180
Study: 37597873

Group type: EXPERIMENTAL
Intervention: OnTrack intervention (12-week package including movement targets, activity tracking, motivational messaging, self-management coaching)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: OnTrack intervention (activity tracking)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: OnTrack intervention (motivational messaging)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: OnTrack intervention (self-management coaching)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: OnTrack intervention (remote monitoring)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: OnTrack intervention (coaching role)
Number of subjects: 11
Study: 37597877

Group type: EXPERIMENTAL
Intervention: Culturally adapted counselling (CAC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Waiting list (WL)
Number of subjects: 120
Study: 37597969

Group type: EXPERIMENTAL
Intervention: 9 mg BI 1015550
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 18 mg BI 1015550
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups (9 mg, 18 mg, placebo)
Number of subjects: 0
Study: 37598000

Group type: EXPERIMENTAL
Intervention: Semaphorins and their receptors (plexins and neuropilins) as regulatory signals in pancreatic cancer treatment
Number of subjects: 0
Study: 37598032

Group type: EXPERIMENTAL
Intervention: Robot-assisted simple enucleation (RASE)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Standard robot-assisted partial nephrectomy (sRAPN)
Number of subjects: 380
Study: 37598161

Group type: EXPERIMENTAL
Intervention: Non-social hassles intensity for the worsened group
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Non-social hassles intensity for the improved group
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Frequency of non-social uplifts for the worsened group
Number of subjects: 128

Group type: COMPARATOR
Intervention: Work status for non-improved groups
Number of subjects: 128
Study: 37598176

Group type: EXPERIMENTAL
Intervention: sEMG-controlled serious games with MYO Armband® and conventional rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional rehabilitation only
Number of subjects: 0
Study: 37598194

Group type: EXPERIMENTAL
Intervention: P11-4
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Nanosilver Fluoride (NSF)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sodium Fluoride (NaF)
Number of subjects: 66
Study: 37598196

Group type: EXPERIMENTAL
Intervention: Supervised exercise consisting of high-intensity interval training on a stationary exercise bike and machine-based progressive resistance training offered three times a week for 24 weeks during NACT
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Supervised exercise
Number of subjects: 120
Study: 37598236

Group type: EXPERIMENTAL
Intervention: Methylation-sensitive restriction enzyme digestion followed by sequencing (MRE-Seq) using cfDNA with SacII enzyme digestion.
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Cancer signal origin (CSO) model using deep neural network (DNN) analysis.
Number of subjects: 191
Study: 37598327

Group type: EXPERIMENTAL
Intervention: tDCS directed to the prefrontal cortex for 30 minutes
Number of subjects: 41

Group type: COMPARATOR
Intervention: Baseline performance
Number of subjects: 41
Study: 37598358

Group type: EXPERIMENTAL
Intervention: Minimally invasive distal pancreatectomy (MIDP) for frail patients (n=79)
Number of subjects: 2212

Group type: COMPARATOR
Intervention: Minimally invasive distal pancreatectomy (MIDP) for nonfrail patients (n=2133)
Number of subjects: 2212

Group type: EXPERIMENTAL
Intervention: Minimally invasive distal pancreatectomy (MIDP) for patients with mFI ≥0.27
Number of subjects: 2212
Study: 37598389

Group type: EXPERIMENTAL
Intervention: Financial micro-incentive (R50 [$3] food voucher) for rapid HIV testing
Number of subjects: 15675

Group type: COMPARATOR
Intervention: Testing only (control arm)
Number of subjects: 15675
Study: 37598625

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Kundalini Yoga
Number of subjects: 226

Group type: COMPARATOR
Intervention: Stress Education (Control)
Number of subjects: 226
Study: 37598656

Group type: EXPERIMENTAL
Intervention: Ripretinib 150 mg once daily
Number of subjects: 453

Group type: COMPARATOR
Intervention: Sunitinib 50 mg once daily (4 weeks on/2 weeks off)
Number of subjects: 453
Study: 37598747

Group type: EXPERIMENTAL
Intervention: 3D optical imaging (3DO)
Number of subjects: 95
Study: 37598748

Group type: EXPERIMENTAL
Intervention: New Nordic Renal Diet (NNRD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Habitual diet
Number of subjects: 60
Study: 37598750

Group type: EXPERIMENTAL
Intervention: 15g whey protein (ERW15, n = 10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 35g whey protein (ERW35, n = 10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 60g whey protein (ERW60, n = 10)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 35g whey protein after energy balanced diet (EBW35, n = 10)
Number of subjects: 40
Study: 37598795

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose as treatment for heart failure with iron deficiency
Number of subjects: 3065

Group type: COMPARATOR
Intervention: HFrEF therapy including beta-blocker
Number of subjects: 3065

Group type: COMPARATOR
Intervention: HFrEF therapy including ARNI
Number of subjects: 3065

Group type: COMPARATOR
Intervention: HFrEF therapy including MRA
Number of subjects: 3065
Study: 37598862

Group type: EXPERIMENTAL
Intervention: Peroral endoscopic myotomy (POEM)
Number of subjects: 54
Study: 37598863

Group type: EXPERIMENTAL
Intervention: Conventional myotomy (CM)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Oblique fiber-sparing myotomy (OFS)
Number of subjects: 115
Study: 37599360

Group type: EXPERIMENTAL
Intervention: Physical training combined with cognitive training
Number of subjects: 62

Group type: COMPARATOR
Intervention: Physical training alone
Number of subjects: 62
Study: 37599886

Group type: EXPERIMENTAL
Intervention: Social Cognition Interaction Training (SCIT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 51
Study: 37599908

Group type: EXPERIMENTAL
Intervention: Parsaclisib 2.5 mg QD (daily dosing group)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Parsaclisib 20 mg QD for 8 weeks, then either 20 mg once-weekly or 2.5 mg QD
Number of subjects: 161
Study: 37600483

Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy (DC)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Craniotomy
Number of subjects: 336
Study: 37600550

Group type: EXPERIMENTAL
Intervention: Quercetin aglycone 250 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Quercetin aglycone 500 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Quercetin aglycone 1000 mg
Number of subjects: 10
Study: 37600800

Group type: EXPERIMENTAL
Intervention: 1/10 dose of Sputnik V vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1/5 dose of Sputnik V vaccine
Number of subjects: 0
Study: 37600829

Group type: EXPERIMENTAL
Intervention: Allocetra™-OTS (apoptotic cells)
Number of subjects: 21
Study: 37600852

Group type: EXPERIMENTAL
Intervention: BIO-initiated
Number of subjects: 2927

Group type: COMPARATOR
Intervention: BIO-non-initiated
Number of subjects: 2927
Study: 37600866

Group type: EXPERIMENTAL
Intervention: Peritoneal bridging
Number of subjects: 112

Group type: COMPARATOR
Intervention: Nonclosure
Number of subjects: 112
Study: 37600876

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic-normoglycemic clamp (HNC) initiated by infusing insulin at 2 mU/kg/min and administering dextrose to maintain normoglycemia (4.0-6.0 mmol/L).
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic-normoglycemic clamp (HNC)
Number of subjects: 34
Study: 37600936

Group type: EXPERIMENTAL
Intervention: nal-IRI + 5-FU/LV
Number of subjects: 56
Study: 37600959

Group type: EXPERIMENTAL
Intervention: PSE syndrome test
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Animal naming test (ANT)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Critical flicker frequency (CFF)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Combination of all three tests (PSE, ANT, CFF)
Number of subjects: 84
Study: 37601010

Group type: EXPERIMENTAL
Intervention: Romiplostim (1 to 10 μg/kg for 9 weeks)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 37601238

Group type: EXPERIMENTAL
Intervention: Single-path adrenal venous sampling (SP)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Multipath adrenal venous sampling (MP)
Number of subjects: 200
Study: 37601688

Group type: EXPERIMENTAL
Intervention: Personalized ctDNA monitoring assay utilizing tissue-based FoundationOne
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 396

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 396
Study: 37601786

Group type: EXPERIMENTAL
Intervention: ANI monitor-based nociception control
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional nociception control (remifentanil based on blood pressure and heart rate)
Number of subjects: 72
Study: 37601885

Group type: EXPERIMENTAL
Intervention: Quadruplet therapy (daratumumab, carfilzomib, lenalidomide, and dexamethasone) followed by autologous hematopoietic cell transplantation (AHCT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-AHCT consolidation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active surveillance (MRD-SURE) after achieving MRD negativity
Number of subjects: 0
Study: 37602251

Group type: EXPERIMENTAL
Intervention: Reflex locomotion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bobath concept
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37602376

Group type: EXPERIMENTAL
Intervention: FFR-guided PCI using zotarolimus drug-eluting stents
Number of subjects: 1500

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: FFR-guided PCI
Number of subjects: 1500
Study: 37602418

Group type: EXPERIMENTAL
Intervention: Topical repellents
Number of subjects: 61651
Study: 37602458

Group type: EXPERIMENTAL
Intervention: Genotyping group (high-risk subgroup received candesartan 8 mg/day for 6 weeks; low-risk subgroup received perindopril 4 mg/day)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Genotyping group
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (not genotyped, received perindopril 4 mg/day)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Low-risk subgroup
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 68
Study: 37602534

Group type: EXPERIMENTAL
Intervention: MD-ICS/LABA
Number of subjects: 38276

Group type: EXPERIMENTAL
Intervention: HD-ICS/LABA
Number of subjects: 38276

Group type: EXPERIMENTAL
Intervention: MD-ICS/LAMA
Number of subjects: 38276

Group type: EXPERIMENTAL
Intervention: HD-ICS
Number of subjects: 38276

Group type: COMPARATOR
Intervention: MD-ICS
Number of subjects: 38276

Group type: COMPARATOR
Intervention: ICS/LABA
Number of subjects: 38276
Study: 37602537

Group type: EXPERIMENTAL
Intervention: GET2HOME transition bundle intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard hospital-based care coordination discharge process
Number of subjects: 0
Study: 37602906

Group type: EXPERIMENTAL
Intervention: START intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 37603048

Group type: EXPERIMENTAL
Intervention: Zosuquidar (Zos) plus gemtuzumab ozogamicin (GO)
Number of subjects: 41
Study: 37603090

Group type: EXPERIMENTAL
Intervention: E/MILOS repair
Number of subjects: 615
Study: 37603097

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37603106

Group type: EXPERIMENTAL
Intervention: Predictive score for pneumothorax occurrence
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Validation cohort
Number of subjects: 498
Study: 37603205

Group type: EXPERIMENTAL
Intervention: Netarsudil 0.02% QD
Number of subjects: 245

Group type: COMPARATOR
Intervention: Ripasudil 0.4% BID
Number of subjects: 245
Study: 37603325

Group type: EXPERIMENTAL
Intervention: Direct transport to an EVT-capable stroke center (n=137)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Transfer to the nearest local stroke center (n=165)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Direct transport to an EVT-capable stroke center
Number of subjects: 302
Study: 37603328

Group type: EXPERIMENTAL
Intervention: Teriflunomide, 14 mg daily
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 37603505

Group type: EXPERIMENTAL
Intervention: Postoperative hypoxemia group (OI ≤ 200 mm Hg)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: ANG II concentration
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: cTnI
Number of subjects: 88
Study: 37603600

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 2627

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2627
Study: 37603816

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus carboplatin and pemetrexed
Number of subjects: 40
Study: 37603835

Group type: EXPERIMENTAL
Intervention: Treat-to-target strategy with pan-enteric capsule endoscopy (PCE)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Complete mucosal healing (MH) at 52 weeks
Number of subjects: 46
Study: 37603846

Group type: EXPERIMENTAL
Intervention: Inflammatory bowel disease (IBD) patients
Number of subjects: 3898
Study: 37603935

Group type: EXPERIMENTAL
Intervention: Supervised foot-ankle strengthening exercise program (3 times a week for 8 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care and recommendations of the healthcare team
Number of subjects: 0
Study: 37604132

Group type: EXPERIMENTAL
Intervention: Breath analysis using gas chromatography-mass spectrometry (GC/MS)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Children with asthma or wheeze
Number of subjects: 142
Study: 37604516

Group type: EXPERIMENTAL
Intervention: Sevoflurane and Dexmedetomidine A
Number of subjects: 52

Group type: COMPARATOR
Intervention: Sevoflurane and Saline 0.9% B
Number of subjects: 52
Study: 37604629

Group type: EXPERIMENTAL
Intervention: Dolutegravir and lamivudine (DTG/3TC)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Dolutegravir, abacavir, and lamivudine (DTG/ABC/3TC)
Number of subjects: 70